German science and technology group Merck is open to more acquisitions for its Life Science business after announcing in May ...

The German company said booming artificial-intelligence demand would help its electronics sales grow faster than previously ...

Merck KGaA cut its mid-term sales growth target for its health-care division after a number of high-profile drug trial ...

German science and technology giant Merck on Thursday said it is confident of returning to medium-term growth after a ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

The company has a new logo, designed by Pentagram, that looks incredibly plain — especially compared to previous iterations of the logo that featured a rakish slant, two shades of blue ...

This Merck KGaA 2022 business report presents the course of business throughout the respective business year. The report complies with the disclosure requirement for corporate entities and ...

Sept 25 (Reuters) - Merck (MRK.N), opens new tab said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial testing it in previously ...

In a report released on October 4, Carter Gould from Barclays maintained a Buy rating on Merck & Company (MRK – Research Report), with a price target of $140.00. The company’s shares closed ...

Merck's recent decline is due to reduced profit guidance and FDA decisions, but shares are at a support level that is likely to hold. Keytruda remains a key revenue driver, with potential for ...

(RTTNews) - Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development collaboration to evaluate the combination of Exelixis ...

Merck & Co. has picked up options on two Evaxion Biotech vaccine candidates, paying $3.2 million and dangling more than $1 billion in milestones for the chance to pick up preclinical prospects ...